Larson S M, Macapinlac H A, Scott A M, Divgi C R
Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
Acta Oncol. 1993;32(7-8):709-15. doi: 10.3109/02841869309096125.
Human tumors express antigenic sites that can serve as targets for radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors in vivo. Over the last decade, nearly 200 clinical trials have been performed which demonstrate that tumors can be detected with excellent sensitivity and specificity. Tumors which are otherwise occult, particularly for colorectal (anti-CEA and anti-TAG-72 antibodies) and ovarian cancer (anti-TAG-72 and anti-HMFG), are detected in a significant fraction of problem patients. Therapy using radiolabeled antibodies has been effective in lymphomas, leukemias and neuroblastomas, and is beginning to show promise in other solid tumors. Biologic characterization of tumors is likely to become more and more important in the future as monoclonal antibodies against oncogene products, such as her-2-neu, are developed. Development of new antibody forms through genetic engineering techniques, and the continual evolution toward higher resolution imaging instruments, such as PET and SPECT, will lead to further clinical improvements in cancer detection.
人类肿瘤表达抗原位点，这些位点可作为放射性标记单克隆抗体的靶点，用于体内人类肿瘤的诊断、治疗和生物学特性鉴定。在过去十年中，已经进行了近200项临床试验，这些试验表明肿瘤能够以优异的灵敏度和特异性被检测到。在相当一部分疑难患者中，原本隐匿的肿瘤，特别是结直肠癌（抗CEA和抗TAG - 72抗体）和卵巢癌（抗TAG - 72和抗HMFG）被检测出来。使用放射性标记抗体的治疗在淋巴瘤、白血病和神经母细胞瘤中已取得成效，并且在其他实体瘤中也开始显示出前景。随着针对癌基因产物（如her - 2 - neu）的单克隆抗体的开发，肿瘤的生物学特性鉴定在未来可能会变得越来越重要。通过基因工程技术开发新的抗体形式，以及向更高分辨率成像仪器（如PET和SPECT）的不断演进，将在癌症检测方面带来进一步的临床改善。
